Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Daily Tech News Seychelles.
Press releases published on September 29, 2025
Artelo Biosciences Announces Proposed Underwritten Public Offering
SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
Ramsey Theory Group CEO Dan Herbatschek Unveils Ethical AI Roadmap to Drive Transformation — Without Sacrificing Human Jobs
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ramsey Theory Group, a leading provider of software development, quantitative analysis, information technology, cybersecurity, digital marketing, and product development, announced today a pioneering initiative: …
Altai Announces Sale of Cessford Oil Wells Property
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced today that it has sold its ownership of a 50% working interest in the oil wells property located in Cessford, Alberta, comprised of 4 oil …
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1 63% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“ORR”) in evaluable …
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …
Le traitement continue de présenter un profil de tolérance favorable avec une faisabilité d’injection confirmée chez les 103 patients lourdement prétraités atteints de CETEC R/M naïfs ou résistants aux anti-PD-1. Chez les patients naïfs aux anti-PD-1 …
Voxtur Announces Purchase of Secured Indebtedness by Hale Capital Partners
Voxtur Announces Purchase of Secured Indebtedness by Hale Capital Partners TORONTO and TAMPA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) ("Voxtur" or the "Company"), a North American technology company …
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation …
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug …
Viomi Celebrates 7th Nasdaq Anniversary with New Brand Campaign and U.S. Launch of AI Alkaline Mineral Water Purifier, MASTER M1
GUANGZHOU, China, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd. (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading innovator of home water solutions in China, today celebrated the 7th anniversary of its Nasdaq listing by announcing two …
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue …
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE …
MAIA Biotechnology Announces $2.25 Million Private Placement
CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into …
IDT Corporation Reports Fourth Quarter and Fiscal Year 2025 Results
4Q25 Gross Profit +12% to $114 million; FY 2025 Gross Profit +14% to $446 million 4Q25 Income from Operations +9% to $22 million; Adjusted EBITDA +33% to $33 million FY 2025 Income from Operations +55% to $100 million; Adjusted EBITDA +43% to $129 million, …
American Rebel Holdings, Inc. (NASDAQ: AREB) and TSR Nitro Celebrate the American Rebel Beer Dodge Hellcat Victory at NHRA Midwest Nationals—Matt Hagan Wins Big in St. Louis
Matt Hagan Powers American Rebel to Victory at NHRA Midwest Nationals—American Rebel Beer Dodge Hellcat Claims First Win of 2025 Nashville, TN, Sept. 29, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) American Rebel Beverages, and …
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunities Upon completion, the royalty management company will manage royalties and milestone payments from financial …
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 …
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS …
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their …
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on September 25, 2025, …